
FDA approves venglustat, the first oral therapy for Type 3 Gaucher neurological symptoms.
Innovators and generics makers are staking out positions on follow-on proteins and other manufacturing issues.
over 21 years ago
April 2005over 21 years ago
Management Controls for GMP Complianceover 21 years ago
PAT and Process Understanding: A Call to Armsover 21 years ago
Cold Chain Concernsover 21 years ago
Evolutions in Direct Compressionover 21 years ago
X-ray Microtomography of Solid Dosage Formsover 21 years ago
Orient Express




